Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Remitting MS (RRMS)”

66 trials

Showing 20 of 66 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04578639
What this trial is testing

Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Haukeland University Hospital 214
Not applicableNot Yet RecruitingNCT07292480
What this trial is testing

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Centre Hospitalier Universitaire de Nīmes 84
Testing effectiveness (Phase 2)WithdrawnNCT00986960
What this trial is testing

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis
University at Buffalo
Not applicableStudy completedNCT01233245
What this trial is testing

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Who this might be right for
Relapsing Remitting MS (RRMS)Secondary Progressive MS (SPMS)
Bayer 1,077
Not applicableStudy completedNCT01592097
What this trial is testing

Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS

Who this might be right for
Multiple Sclerosis
University of Southern California 51
Post-approval studies (Phase 4)WithdrawnNCT02568111
What this trial is testing

Brimonidine Tartrate for the Treatment of Injection Related Erythema

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen
Post-approval studies (Phase 4)Looking for participantsNCT06733922
What this trial is testing

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)
Novartis Pharmaceuticals 224
Not applicableStudy completedNCT03408093
What this trial is testing

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

Who this might be right for
Multiple Sclerosis
Bayer 120
Not applicableStudy completedNCT00461396
What this trial is testing

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Bayer 104
Testing effectiveness (Phase 2)Ended earlyNCT03239860
What this trial is testing

Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GeNeuro SA 220
Testing effectiveness (Phase 2)Study completedNCT00882999
What this trial is testing

Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Eli Lilly and Company 245
Large-scale testing (Phase 3)Active Not RecruitingNCT03477500
What this trial is testing

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

Who this might be right for
Multiple Sclerosis
Haukeland University Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT01037907
What this trial is testing

Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Boston Scientific Corporation 173
Testing effectiveness (Phase 2)Study completedNCT02493049
What this trial is testing

Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University of Calgary 17
Not applicableActive Not RecruitingNCT03983681
What this trial is testing

Evaluation of a Theory-Driven Manualized Approach to Improving New Learning and Memory in MS

Who this might be right for
Multiple Sclerosis
Kessler Foundation 120
Not applicableStudy completedNCT03768648
What this trial is testing

Cognition and MRI Markers in MS Patients With Aubagio® Treatment

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
University Hospital, Bordeaux 75
Not applicableStudy completedNCT00818038
What this trial is testing

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 30
Early research (Phase 1)Ended earlyNCT01144351
What this trial is testing

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 32
Not applicableStudy completedNCT01080053
What this trial is testing

Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis, Relapsing Remitting
Merck KGaA, Darmstadt, Germany 306
Large-scale testing (Phase 3)Study completedNCT03093324
What this trial is testing

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 506
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation